Summary of Veeva Systems (VEEV) 2025 Conference Call Company Overview - **Company**: Veeva Systems (VEEV) - **Event**: 2025 Conference at Citi Tech Conference - **Date**: September 04, 2025 Key Points Company Transformation and Strategy - The company is undergoing a transformation and inflection point, focusing on entering new markets and horizontal software, which is seen as the "third act" of Veeva [4][59] - Significant investment in AI is expected to drive change within Veeva and the industry [5] Financial Performance - Q2 billings were subdued due to timing factors, not indicative of long-term business trajectory; revenue and subscription revenue are better indicators of momentum [6][7] - The company raised guidance for the full year across all lines, including revenue, billings, and cash flow, reflecting confidence in the business [7][8] CRM Migration and Competitive Position - Veeva has transitioned from Salesforce to its own Vault CRM, with nine commitments from top 20 pharma companies, indicating strong market traction [9][12] - The migration is expected to yield significant gross margin benefits, with an estimated $80 million in royalty payments to Salesforce being eliminated over time [28] - The company is confident in its ability to win back customers from Salesforce if implementations do not go well [16] Crossix Business Performance - Crossix is performing well, with over $200 million in ARR, driven by investments in product development and a dedicated field team [30][31] - The Audiences business within Crossix is experiencing strong growth, supported by healthy customer marketing budgets [33] Partnership with IQVIA - A new partnership with IQVIA has been established, resolving a long-standing legal dispute and creating opportunities for collaboration in data and clinical markets [35][41] - The partnership is expected to reduce friction for customers and enhance the value proposition of both companies' offerings [41] R&D and Product Development - Veeva has achieved high penetration in the eTMF product, with 20 of the top 20 pharma companies standardized on it, providing a strong foundation for further innovation [52] - The company is focused on expanding its suite of applications in R&D, with a low current penetration rate of around 15% [55] Horizontal Software Market - Veeva is exploring opportunities in the horizontal enterprise application market, which is seen as a long-term growth strategy [59][60] - The company aims to leverage its software capabilities to innovate in this space, emphasizing a commitment to customer success [60] Market Environment and Customer Sentiment - Despite uncertainties in the industry, life sciences companies are continuing to modernize their systems and execute their projects effectively [62][63] - The company remains optimistic about its growth trajectory, supported by a diverse portfolio of products and a strong execution strategy [66][68] Future Outlook - Veeva's long-term targets imply low teens growth, supported by a broad-based portfolio approach and multiple products entering steep adoption phases [65][66] - The company is focused on leveraging AI to enhance quality and speed, rather than solely for margin accretion [70] Additional Insights - The transition to Vault CRM is expected to enhance product excellence and customer success, which are core to Veeva's strategy [27][28] - The company is committed to competing in the data market while maintaining a respectful relationship with IQVIA [45][49]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $789 million, with non-GAAP operating income of $353 million, exceeding guidance [6][7]. - The company expressed confidence in its $6 billion revenue plan over the next five years, indicating strong performance and growth potential [22]. Business Line Data and Key Metrics Changes - R&D subscriptions and services showed significant upside, indicating a broad-based growth across all areas [19][40]. - The resolution of the lawsuit with IQVIA is expected to enhance the commercial cloud offerings, particularly in integrating IQVIA data into Veeva's products [12][14]. Market Data and Key Metrics Changes - The company reported strong execution across its business segments, with no specific areas of weakness despite macroeconomic uncertainties [124]. - The commercial cloud segment is anticipated to benefit from the resolution with IQVIA, allowing for a more comprehensive solution for customers [73][86]. Company Strategy and Development Direction - Veeva is focusing on enhancing its AI capabilities, with plans to integrate AI agents into its existing platforms, which is expected to create significant value for the industry over time [28][30]. - The company aims to leverage its structural advantages in the life sciences sector to lead in industry-specific cloud applications and AI agents [46][48]. Management's Comments on Operating Environment and Future Outlook - Management noted that while there is elevated uncertainty in the macro environment, customer engagement remains strong, and the pipeline is building effectively [124]. - The company does not expect immediate revenue contributions from the IQVIA resolution but sees it as a long-term growth driver [90]. Other Important Information - The company is working on refining its migration tooling to facilitate customer transitions to the Vault CRM, with over 20 customers already migrated and 300 more planned [106]. - Veeva's business consulting services are seen as a critical component in driving AI adoption and helping customers navigate changes in workflows [111][115]. Q&A Session Summary Question: What led to the resolution of the lawsuit with IQVIA? - The resolution was driven by changes in the industry landscape and a mutual recognition that collaboration would benefit both companies and their customers [12][14]. Question: How does the resolution with IQVIA unlock new opportunities? - It removes previous barriers to integrating IQVIA data into Veeva's products, enhancing the commercial cloud offerings and allowing for more comprehensive solutions [14][73]. Question: What is the outlook for R&D subscription growth? - R&D subscriptions are expected to continue growing, supported by strong execution across all areas and a stable environment [40][76]. Question: How does Veeva plan to leverage AI in its offerings? - Veeva plans to integrate AI agents into its platforms, enhancing productivity and creating new revenue opportunities over time [28][30]. Question: What is the customer reaction to the IQVIA resolution? - Customer feedback has been overwhelmingly positive, as the resolution alleviates previous integration issues and opens up new possibilities for collaboration [34][36]. Question: What are the expectations for commercial subscriptions moving forward? - The company anticipates continued strength in commercial subscriptions, particularly driven by the Crossix product, despite some flatness in the recent quarter [74][76]. Question: How does Veeva differentiate itself in the AI space? - Veeva's structural advantage lies in its deep industry-specific applications, allowing for seamless integration of AI agents into existing workflows [94][96].